What is Ironwood Pharmaceuticals's SG&A?

Ironwood Pharmaceuticals (IRWD) reported SG&A of $12.03M in Q1 2026.

How has Ironwood Pharmaceuticals's SG&A changed year-over-year?

Ironwood Pharmaceuticals's SG&A decreased by 50.4% year-over-year, from $24.26M to $12.03M.

What is the long-term trend for Ironwood Pharmaceuticals's SG&A?

Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's SG&A has grown at a -7.2% compound annual growth rate (CAGR), from $111.13M to $82.26M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ironwood Pharmaceuticals IRWD SG&A

SG&A at other companies

Bausch Health CompaniesBHC

$861M-0.7%

ArdelyxARDX

$102.27M+22.9%

Rigel PharmaceuticalsRIGL

$30.65M+10.6%

ANI PharmaceuticalsANIP

$73.66M-3.8%

Catalyst PharmaceuticalCPRX

$49.32M+5.1%

Lexicon PharmaceuticalsLXRX

$9.23M-20.5%

Other financials

Income statement

See full

Revenue$106.5M+159%

Operating income$72.6M+349%

Net income$40.8M+209%

EPS (diluted)$0.24+204%

Balance sheet

See full

Cash & equivalents$220.5M+103%

Total debt$212.4M+1,323%

Total equity-$217.1M+35.0%

Total assets$434.6M+32.8%

Cash flow

See full

Operating cash flow$5.1M-74.3%

CapEx-—

Free cash flow$74.6M+390%

Valuation

See full

Market cap$632.12M+457%

Enterprise value$624M+3,024%

P/E6.2×—

P/S1.8×+1.4×

Profitability

See full

Gross margin99.2%—

Operating margin55.4%+38.7pp

Net margin28.3%+22.3pp

FCF margin24.7%-11.1pp

Returns & leverage

See full

Return on equity29.7%-138pp

Debt / equity0×-0.5×

Current ratio1.4×-1.9×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ironwood Pharmaceuticals's SG&A?: Ironwood Pharmaceuticals (IRWD) reported SG&A of $12.03M in Q1 2026.
How has Ironwood Pharmaceuticals's SG&A changed year-over-year?: Ironwood Pharmaceuticals's SG&A decreased by 50.4% year-over-year, from $24.26M to $12.03M.
What is the long-term trend for Ironwood Pharmaceuticals's SG&A?: Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's SG&A has grown at a -7.2% compound annual growth rate (CAGR), from $111.13M to $82.26M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.